论文部分内容阅读
传统的零级释药和一级速率释药的缓/控释制剂在较长时间内比普通制剂或多或少地维持了恒定的血药浓度,保证了缓释或药物的长效,在临床治疗中起到积极作用。随着时间推移,缓/控释制剂也暴露出不足,满足不了临床需求,如在治疗期间反复用药,使某些药物缓/控释制剂,造成疗效下降,副作用增大,尤其受“首过效应”大量代谢降解的药物(如左旋多巴等)生物降解量增大,影响了生物利用度。
The traditional zero-grade drug release and the first-rate / controlled-release slow / controlled release formulations maintain a more or less constant plasma concentration over a longer period of time, ensuring sustained release or long-acting drugs Clinical treatment has played a positive role. With the passage of time, slow / controlled release formulations are also exposed inadequate to meet clinical needs, such as repeated treatment during treatment, the slow / controlled release of certain drugs, resulting in decreased efficacy, increased side effects, especially by the “first Effect ”a large number of metabolic degradation of drugs (such as levodopa, etc.) increase the amount of biodegradation, affecting the bioavailability.